Literature DB >> 12441926

Phase II trial of radio frequency ablation of renal cancer: evaluation of the kill zone.

Brian R Matlaga1, Ronald J Zagoria, Ralph D Woodruff, Frank M Torti, M Craig Hall.   

Abstract

PURPOSE: We report on the pathological evaluation of renal tumors after intraoperative radio frequency ablation performed immediately before surgical nephrectomy.
MATERIALS AND METHODS: Ten patients with renal tumors were enrolled in a prospective, Institutional Review Board approved phase II trial of radio frequency ablation. Following surgical exposure of the kidney a single 12-minute radio frequency ablation of the tumor was performed using the Radionics Cool-tip RF Radio Frequency Ablation System (Radionics, Burlington, Massachusetts). The tumor was then excised via radical or partial nephrectomy. Gross and histological evaluations of the tumor were performed, including evaluation with nicotinamide adenine dinucleotide vital staining.
RESULTS: All 10 tumors were confirmed histologically to be renal cell carcinoma. Mean tumor size was 3.2 cm. (range 1.4 to 8.0). Of the 10 tumors 8 were completely ablated with a mean treatment margin of 6.75 mm. (range 2 to 13). Of the 2 tumors that were incompletely treated 1 never attained a temperature sufficient for tissue destruction and the other measured 8 cm., far exceeding the expected ablation volume of treatment protocol.
CONCLUSIONS: This study represents the initial report of the histological outcome of saline cooled radio frequency ablation of renal tumors. Our data indicate that it can completely destroy renal cancers while transmitting minimal collateral damage to surrounding renal parenchyma. Further investigation is required to determine long-term oncological outcome.

Entities:  

Mesh:

Year:  2002        PMID: 12441926     DOI: 10.1097/01.ju.0000036614.65812.38

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  16 in total

1.  Percutaneous US-guided RF thermal ablation for malignant renal tumors: preliminary results in 13 patients.

Authors:  Andrea Veltri; Giuseppina De Fazio; Valeria Malfitana; Giuseppe Isolato; Dario Fontana; Alessandro Tizzani; Giovanni Gandini
Journal:  Eur Radiol       Date:  2004-07-27       Impact factor: 5.315

2.  Laparoscopic radiofrequency ablation-assisted enucleation of Xp11.2 translocation renal cell carcinoma: A case report.

Authors:  Linfeng Xu; Rong Yang; Wei Wang; Yifen Zhang; Weidong Gan
Journal:  Oncol Lett       Date:  2014-06-18       Impact factor: 2.967

Review 3.  [Recurrent disease in renal cell carcinoma. "Local recurrence" after kidney-sparing and radical resection].

Authors:  M Löhr; D Rohde
Journal:  Urologe A       Date:  2005-04       Impact factor: 0.639

Review 4.  Targeted hyperthermia using metal nanoparticles.

Authors:  Paul Cherukuri; Evan S Glazer; Steven A Curley
Journal:  Adv Drug Deliv Rev       Date:  2009-11-10       Impact factor: 15.470

5.  Radio frequency ablation of small renal tumors:: intermediate results.

Authors:  J J Hwang; M M Walther; S E Pautler; J A Coleman; J Hvizda; James Peterson; W M Linehan; B J Wood
Journal:  J Urol       Date:  2004-05       Impact factor: 7.450

Review 6.  [Energy ablative therapy of renal tumours].

Authors:  H C Klingler
Journal:  Urologe A       Date:  2007-05       Impact factor: 0.639

Review 7.  Radiofrequency ablation of renal tumors.

Authors:  Brian R Matlaga; Ronald J Zagoria; Peter E Clark; M Craig Hall
Journal:  Curr Urol Rep       Date:  2004-02       Impact factor: 3.092

8.  Review of the efficacy and safety of radiofrequency ablation for the treatment of small renal masses.

Authors:  Regina El Dib; Naji J Touma; Anil Kapoor
Journal:  Can Urol Assoc J       Date:  2009-04       Impact factor: 1.862

Review 9.  Radiofrequency ablation of renal tumors.

Authors:  Andreas H Mahnken; Rolf W Günther; Josef Tacke
Journal:  Eur Radiol       Date:  2004-05-19       Impact factor: 5.315

Review 10.  [Percutaneous radiofrequency ablation of renal cell cancer].

Authors:  J Tacke; A H Mahnken
Journal:  Radiologe       Date:  2004-04       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.